clindamycin
(klin da mye' sin)
clindamycin hydrochloride
Oral:
Cleocin, Dalacin C (CAN)
clindamycin palmitate hydrochloride
Oral:
Cleocin Pediatric
clindamycin phosphate
Oral, parenteral, topical dermatologic solution for acne, vaginal preparation:
Cleocin Phosphate, Cleocin T, Cleocin Vaginal Ovules, Clinda-Derm (CAN), Clindagel, ClindaMax, Clindets, Dalacin C (CAN)
Pregnancy Category B
Drug class
Lincosamide antibiotic
Therapeutic actions
Inhibits protein synthesis in susceptible bacteria, causing cell death.
Indications
· Systemic administration: Serious infections caused by susceptible strains of anaerobes, streptococci, staphylococci, pneumococci; reserve use for penicillin-allergic patients or when penicillin is inappropriate; less toxic antibiotics (erythromycin) should be considered
· Parenteral: Treatment of septicemia caused by staphylococci, streptococci; acute hematogenous osteomyelitis; adjunct to surgical treatment of chronic bone and joint infections due to susceptible organisms; do not use to treat meningitis; does not cross the blood–brain barrier.
· Topical dermatologic solution: Treatment of acne vulgaris
· Vaginal preparation: Treatment of bacterial vaginosis
Contraindications and cautions
Systemic administration
· Contraindicated with allergy to clindamycin, history of asthma or other allergies, tartrazine (in 75- and 150-mg capsules); hepatic or renal dysfunction; lactation.
· Use cautiously in newborns and infants due to benzyl alcohol content; associated with gasping syndrome.
Topical dermatologic solution, vaginal preparation
· Contraindicated with allergy to clindamycin or lincomycin.
· Use caution with history of regional enteritis or ulcerative colitis; history of antibiotic-associated colitis.
Available forms
Capsules—75, 150, 300 mg; granules for oral solution—75 mg/5 mL; injection—150 mg/mL; topical gel—1%; topical lotion—1%; topical suspension—1%; vaginal cream—2%; vaginal suppository—100 mg
Dosages
ADULTS
Oral
150–300 mg q 6 hr, up to 300–450 mg q 6 hr in more severe infections.
Parenteral
600–2,700 mg/day in two to four equal doses; up to 4.8 g/day IV or IM may be used for life-threatening situations.
Vaginal
One applicator (100 mg clindamycin phosphate) intravaginally, preferably at hs for 7 consecutive days; or insert vaginal suppository, preferably at hs for 7 consecutive days, 3 days for Cleocin Vaginal Ovules.
Topical
Apply a thin film to affected area bid.
PEDIATRIC PATIENTS
Oral
For clindamycin HCl, 8–20 mg/kg/day in three or four equal doses. For clindamycin palmitate HCl, 8–25 mg/kg/day in three or four equal doses; for children weighing < 10 kg, use 37.5 mg tid as the minimum dose.
Parenteral
Neonates: 15–20 mg/kg/day in three or four equal doses.
> 1 mo: 15–40 mg/kg/day in three or four equal doses or 350 mg/m2/day to 450 mg/m2/day.
GERIATRIC PATIENTS OR PATIENTS WITH RENAL FAILURE
Reduce dose, and monitor patient's serum levels carefully.
Pharmacokinetics
Route | Onset | Peak | Duration |
Oral | Varies | 1–2 hr | 8–12 hr |
IM | 20–30 min | 1–3 hr | 8–12 hr |
IV | Immediate | Minutes | 8–12 hr |
Topical | Minimal systemic absorption | | |
Metabolism: Hepatic; T1/2: 2–3 hr
Distribution: Crosses placenta; enters breast milk
Excretion: Feces, urine
IV facts
Preparation: Store unreconstituted product at room temperature. Reconstitute by adding 75 mL of water to 100-mL bottle of palmitate in two portions. Shake well; do not refrigerate reconstituted solution. Reconstituted solution is stable for 2 wk at room temperature. Dilute reconstituted solution to a concentration of 300 mg/50 mL or more of diluent using 0.9% sodium chloride injection, 5% dextrose injection, or lactated Ringer's solution. Solution is stable for 16 days at room temperature.
WARNING: Infusion: Do not administer more than 1,200 mg in a single 1-hr infusion. Infusion rates: 300 mg in 50 mL diluent, 10 min; 600 mg in 50 mL diluent, 20 min; 900 mg in 50–100 mL diluent, 30 min; 1,200 mg in 100 mL diluent, 40 min. Rapid infusion can cause cardiac arrest.
Incompatibilities: Do not mix with calcium gluconate, ampicillin, phenytoin, barbiturates, aminophylline, and magnesium sulfate. May be mixed with sodium chloride, dextrose, calcium, potassium, vitamin B complex, kanamycin, gentamicin, penicillin, carbencillin. Incompatible in syringe with tobramycin.
Adverse effects
Systemic administration
· CV: Hypotension, cardiac arrest (with rapid IV infusion)
· GI: Severe colitis, including pseudomembranous colitis, nausea, vomiting, diarrhea, abdominal pain, esophagitis, anorexia, jaundice, liver function changes
· Hematologic: Neutropenia, leukopenia, agranulocytosis, eosinophilia
· Hypersensitivity: Rashes, urticaria to anaphylactoid reactions
· Local: Pain following injection, induration and sterile abscess after IM injection, thrombophlebitis after IV use
Topical dermatologic solution
· CNS: Fatigue, headache
· Dermatologic: Contact dermatitis, dryness, gram-negative folliculitis
· GI: Pseudomembranous colitis, diarrhea, bloody diarrhea; abdominal pain, sore throat
· GU: Urinary frequency
Vaginal preparation
· GU: Cervicitis, vaginitis, vulvar irritation
Interactions
Systemic administration
Drug-drug
· Increased neuromuscular blockade with neuromuscular blocking agents
· Decreased GI absorption with kaolin, aluminum salts
Nursing considerations
Assessment
· History: Allergy to clindamycin, history of asthma or other allergies, allergy to tartrazine (in 75- and 150-mg capsules); hepatic or renal dysfunction; lactation; history of regional enteritis or ulcerative colitis; history of antibiotic associated colitis
· Physical: Site of infection or acne; skin color, lesions; BP; R, adventitious sounds; bowel sounds, output, liver evaluation; CBC, LFTs, renal function tests
Interventions
Systemic administration
· Culture infection before therapy.
· Administer oral drug with a full glass of water or with food to prevent esophageal irritation.
· Do not give IM injections of more than 600 mg; inject deep into large muscle to avoid serious problems.
· Do not use for minor bacterial or viral infections.
· Monitor LFTs and renal function tests, and blood counts with prolonged therapy.
Topical dermatologic administration
· Keep solution away from eyes, mouth and abraded skin or mucous membranes; alcohol base will cause stinging. Shake well before use.
· Keep cool tap water available to bathe eye, mucous membranes, abraded skin inadvertently contacted by drug solution.
Vaginal preparation
· Give intravaginally, preferably at hs.
Teaching points
Systemic administration
· Take oral drug with a full glass of water or with food.
· Take full prescribed course of oral drug. Do not stop taking without notifying health care provider.
· You may experience these side effects: Nausea, vomiting (eat frequent small meals); superinfections in the mouth, vagina (use frequent hygiene measures; request treatment if severe).
· Report severe or watery diarrhea, abdominal pain, inflamed mouth or vagina, skin rash or lesions.
Topical dermatologic administration
· Apply thin film of acne solution to affected area twice daily, being careful to avoid eyes, mucous membranes, abraded skin; if solution contacts one of these areas, flush with lots of cool water.
· Report abdominal pain, diarrhea.
Vaginal preparation
· Use vaginal preparation for 7 or 3 consecutive days, preferably at bedtime. Refrain from sexual intercourse during treatment with this product.
· Report vaginal irritation, itching; diarrhea, no improvement in complaint being treated.
0 comments:
Post a Comment